Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Published in Advanced Melanoma and

Journal Scan / Research · February 16, 2021

First-Line BRAF/MEK Inhibitors vs Anti–PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma

British Journal of Cancer

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Paul Hampel MD

British Journal of Cancer

First-Line BRAF/MEK Inhibitors Versus Anti-PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma Patients: A Propensity-Matched Survival Analysis

Br. J. Cancer 2021 Jan 26;[EPub Ahead of Print], J van Breeschoten, MWJM Wouters, DL Hilarius, JB Haanen, CU Blank, MJB Aarts, FWPJ van den Berkmortel, JB de Groot, GAP Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, WAM Blokx, BJT Tije, AAMV Veldt, A Vreugdenhil, MJ Boers-Sonderen, AJM van den Eertwegh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Melanoma

First-Line BRAF/MEK Inhibitors vs Anti–PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma

Additional Info

First-Line BRAF/MEK Inhibitors Versus Anti-PD-1 Monotherapy in BRAFV600-Mutant Advanced Melanoma Patients: A Propensity-Matched Survival Analysis

Further Reading

Response to Checkpoint Inhibition and Targeted Therapy in Patients With Melanoma With Concurrent Haematological Malignancies

Utility of MIA and MSKCC Nomograms in Selecting Patients With Melanoma for Sentinel Lymph Node Biopsy

Adjuvant Systemic Therapy or Watchful Waiting in Patient With Multiple Comorbidities?

Progression of Disease in a Patient With Previous irAE on Ipi+Nivo; What's Next?

IFN-γ Signature Enables the Selection of Neoadjuvant Treatment in Patients With Stage III Melanoma

Young Patient With Li-Fraumeni Syndrome With Melanoma Metastasis of Unknown Primary

ctDNA-Based Molecular Residual Disease Detection for Treatment Monitoring in Patients With Advanced Melanoma

Decision-Making and HRQoL in Patients With Melanoma Considering Adjuvant Immunotherapy

Recurrence of Disease During Fertility Procedures; Patient Tailored Treatment?

Neoadjuvant–Adjuvant vs Adjuvant-Only Pembrolizumab for Advanced Melanoma

Alternatives and a Reduced Need for Sentinel Lymph Node Biopsy Staging for Melanoma

Recently Updated